Anesiva Announces May 22, 2008 Presentation at Citi Investment Research Global HealthCare ... ( SOUTH SAN FRANCISCO Calif. May 16...)

Anesiva Announces May 22, 2008 Presentation at Citi Investment Research Global HealthCare Conference

Date:5/16/2008

SOUTH SAN FRANCISCO, Calif., May 16 /PRNewswire-FirstCall/ -- Anesiva, Inc. (Nasdaq: ANSV) today announced that John P. McLaughlin, the company's chief executive officer, will present at the Citi Investment Research Global Healthcare Conference in New York City on May 22, 2008 at 9:30 a.m. EDT.

To access the live webcast or the subsequent archived recording, log on to http://www.anesiva.com, go to the Investors page, and click on Events. Please connect to Anesiva's website several minutes prior to the start of the webcast to ensure adequate time for any software download that may be necessary.

About Anesiva and its Diverse Pipeline of Pain Products

Anesiva, Inc. is a late-stage biopharmaceutical company that seeks to be the leader in the development and commercialization of novel pharmaceutical products for pain management. The company has one FDA-approved product, Zingo(TM), for the reduction of pain associated with peripheral venous access procedures in children ages three to 18. In clinical trials, the most common adverse reactions to Zingo were redness (erythema), red dots (petechiae) and swelling (edema). The second product in Anesiva's pipeline, Adlea(TM), reduces pain after only a single administration for weeks to months based on mid-stage clinical trials for site-specific, acute and chronic, moderate-to-severe pain. Anesiva is based in South San Francisco, CA. For more information about Anesiva's leadership in the development of products for pain management, and an overview of the clinical challenges being addressed by its product candidates, go to http://www.anesiva.com.

SOURCE Anesiva, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Post Your Comments:

(Date:5/24/2013)... The news about youth and diabetes keeps getting worse. ... that children who develop Type 2 diabetes are at high ... at a higher rate than people who acquire Type 2 ... 2 diabetes, they seem to be at very high risk ... M.D., professor of pediatric endocrinology in the School of Medicine ...

(Date:5/24/2013)... 2013 Fit Yummy Mummy, a fitness ... who are trying to get rid of the belly ... ideal for women who want to combine exercises with ... ’s Stan Stevenson, prompting an investigative review. , “Holly's ... a wide variety of motivational strategies, nutritional plans, proper ...

(Date:5/24/2013)... The Institute for Integrative Nutrition , the ... has donated $10,000 to the Cleveland Courage Fund , ... Ohio. , “When the news came out on Monday, May ... and her daughter had escaped from a Cleveland home after ... horrified,” said Integrative Nutrition Founder, Director, and Primary Teacher Joshua ...

(Date:5/24/2013)... 2013 General Data Company Inc., ... tracking and data management products and solutions, has ... Inc., (TBS) of Durham, North Carolina, a leading ... for the clinical and research pathology marketplace. TBS ... which provides specialty products and solutions to hospitals, ...

(Date:5/24/2013)... Finding the answer for this is at the centre of ... the Bergen fMRI Group at the University of Bergen (UiB) ... The way they do this is by studying people who ... mental illness. For a five-year period, the group is studying ... report published in Frontiers in Human Neuroscience shows ...

Breaking Medicine News(10 mins):Health News:Youth with type 2 diabetes at much higher risk for heart, kidney disease 2 Health News:Fit Yummy Mummy: Review Examining Holly Rigsby’s Fitness Program Released 2 Health News:Integrative Nutrition Donates $10,000 to the Cleveland Courage Fund 2 Health News:General Data Acquires Triangle Biomedical Sciences 2 Health News:General Data Acquires Triangle Biomedical Sciences 3 Health News:Help at hand for schizophrenics 2

[0] Youth with type 2 diabetes at much higher risk for heart, kidney disease [0] Fit Yummy Mummy: Review Examining Holly Rigsby’s Fitness Program Released [0] Integrative Nutrition Donates $10,000 to the Cleveland Courage Fund [0] General Data Acquires Triangle Biomedical Sciences [0] Help at hand for schizophrenics

... the 13th time, more than any hospital in the U.S. , ... ... (NorthShore) was named one of the nation,s 100 Top Hospitals® by Thomson ... and quality of healthcare. NorthShore has been named a Top 100 Hospital ...

... (April 1, 2009) It appears that a drug ... similar effect on the compulsive behavior of kleptomaniacs it ... the University of Minnesota., The Medical School,s Department of Psychiatry ... ages 17-75, who spent an average of at least one ...

... KUALA LUMPUR, Malaysia, March 31 Rheumatoid arthritis (RA) ... which the body,s defense system attacks the joints through ... lines and lubricates the joints. The most visible symptoms ... of the hands and feet. It can cause fatigue, ...

... LifeCare Holdings, Inc. (the "Company") today announced its operating ... 2008. Three Months Ended December 31, 2008 ... service revenue of $94.2 million for the three months ended ... the same period in 2007 while patient days were unchanged. ...

... Guideline Reached For Quantitative Polymerase Chain ReactionSALT LAKE CITY, ... and the American Association for Clinical Chemistry ... for a key laboratory method called qPCR (or quantitative ... international scientists representing the medical and research fields. qPCR ...

... The U.S. District Court for the District of ... between Alza Corporation, McNeil-PPC, Inc. and Andrx Pharmaceuticals LLC. ... markets CONCERTA(R) (methylphenidate HCI) Extended-Release Tablets CII, said the ... valid or infringed by the filing of Andrx,s Abbreviated ...

NorthShore University HealthSystem Named One of the Nation's Top 100 Hospitals by Thomson Reuters Drug commonly used for alcoholism, drug addiction, curbs urges of compulsive stealers Frost & Sullivan: Rheumatoid Arthritis Therapeutics in Malaysia LifeCare Holdings, Inc. Announces Year-End Results International Scientists Secure Quality in Molecular Diagnostics District Court Decision Received in CONCERTA(R) Patent Case

(Date:5/24/2013)... LOS ANGELES , May 24, 2013 An ... gathered on Saturday, May 18, in Santa ... findings on new lung-sparing therapies for MPM, a rare ... and commonly affects the pleura, the lining of the ... Heart, Lung and Blood Institute, the 3rd Annual International ...

(Date:5/24/2013)... May 24, 2013 In accordance with Rule 17.1 ... 14e-1 of the United States Exchange Act, Echo Pharma Acquisition ... for Elan Corporation (NYSE: ELN). Background ... made an offer for the entire of the issued and ... (the "Original Offer"). On 20 May 2013, ...

(Date:5/23/2013)... 24, 2013 3SBio Inc. (NASDAQ: ... leading China -based biotechnology company ... products, announced today that, at an extraordinary general ... voted in favor of the proposal to authorize ... of merger dated February 8, 2013, among Decade ...

Breaking Medicine Technology:International Mesothelioma Experts Present Promising New Research Findings at the 3rd Annual International Symposium on Lung-Sparing Therapies for Malignant Pleural Mesothelioma 2 International Mesothelioma Experts Present Promising New Research Findings at the 3rd Annual International Symposium on Lung-Sparing Therapies for Malignant Pleural Mesothelioma 3 Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 2 Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 3 Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 4 Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 5 Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 6 Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 7 Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 8 Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 9 3SBio Inc. Announces Shareholders' Approval of the Amended Merger Agreement 2 3SBio Inc. Announces Shareholders' Approval of the Amended Merger Agreement 3

[0] International Mesothelioma Experts Present Promising New Research Findings at the 3rd Annual International Symposium on Lung-Sparing Therapies for Malignant Pleural Mesothelioma [0] Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements [0] 3SBio Inc. Announces Shareholders' Approval of the Amended Merger Agreement

... 16, 2011 Cancer patients in China ... the announcement that a leading cancer center is acquiring ... VAR). This device is the first high dose rate ... leader in radiotherapy systems. Jilin University ...

... 16, 2011 U L ... announced today that it has filed an abbreviated 510(k) application ... label claim to include the management and mitigation of pain. ... a randomized clinical study comparing Altrazeal® to Acquacel® Ag in ...

Cached Medicine Technology:First Varian High Dose Rate Brachytherapy Afterloader Supplied to Leading China Cancer Hospital 2 ULURU Inc. Announces the Filing of a 510(k) Application to Expand Altrazeal®'s Label Claim 2 ULURU Inc. Announces the Filing of a 510(k) Application to Expand Altrazeal®'s Label Claim 3 ULURU Inc. Announces the Filing of a 510(k) Application to Expand Altrazeal®'s Label Claim 4

First Varian High Dose Rate Brachytherapy Afterloader Supplied to Leading China Cancer Hospital ULURU Inc. Announces the Filing of a 510(k) Application to Expand Altrazeal®'s Label Claim

... Detection Of Serum C-Peptide ... Measurement:, Evaluating patients ... Assisting in the classification ... Differentiating insulin dependent patients ...

Inquire...

The Pach IV is the premier product for cornea thickness measurement in conjunction with Glaucoma screening....

Inquire...

Medicine Products:

ACS:180 C-Peptide Assay C-Peptide Pach IV Pachymeter RIDASCREEN Anti-Measles Virus IgM Assay